Banca de QUALIFICAÇÃO: LAILA CHEIBUB COSTA RODRIGUES

Uma banca de QUALIFICAÇÃO de MESTRADO foi cadastrada pelo programa.
STUDENT : LAILA CHEIBUB COSTA RODRIGUES
DATE: 15/06/2023
TIME: 19:00
LOCAL: meet.google.com/grn-nugq-hxq
TITLE:

Evaluation of the performance of the use of corticosteroids and Tocilizumab in hospitalized patients with COVID-19

KEY WORDS:

SARS-CoV-2 ; Corticosteroids; Tocilizumab ; Hospital Sobrasa ; Teixeira de Freitas

PAGES: 41
BIG AREA: Ciências da Saúde
AREA: Medicina
SUBÁREA: Clínica Médica
SPECIALTY: Doenças Infecciosas e Parasitárias
SUMMARY:

With a high rate of transmissibility and dissemination, we experienced the COVID-19 pandemic from March 2020 to May 2023, when the World Health Organization declared its end. The disease caused by the new SARS-CoV-2 coronavirus has high morbidity and mortality in a short period, which has challenged clinical practice regarding drug treatment worldwide. The aim of the study was to evaluate the performance of using corticosteroids alone or associated with tocilizumab in patients hospitalized with COVID-19 at Hospital Sobrasa in Teixeira de Freitas, Bahia. The medical records of patients hospitalized with COVID-19 in a tertiary hospital in the extreme south of Bahia were reviewed. Then, the most relevant epidemiological and clinical-evolutionary aspects were stored in a database for further statistical analysis. From March to December 2020, 184 patients were included, of which 120 (65.22%) were men and 64 (34.78%) women, in a predominant age group between the 3rd and 5th decades of life, and one average of 57.41 years. Among the main associated comorbidities, 72 (39.13%) patients were hypertensive, 44 (23.91%) were diabetic and 80 (43.48%) had no comorbidity. The most common symptoms were: cough 144 (78.26%), dyspnea 131 (71.2%), fever 117 (63.59%), myalgia 73 (39.67%) and 5 patients (2.72%) were asymptomatic. As for the laboratory diagnosis of viral infection, the reverse transcription polymerase chain reaction test (RT-PCR), the rapid TR-antigen test, the TR-antibody test for SARS-COV 2 and serological tests for SARS-COV 2 (ELISA, CLIA and immunofluorescence) were positive in 161 (87%), 16 (8.7%), 5 (2.72%) and 2 (1.09%) cases, respectively. In computed tomography (CT), 97 (52.72%) had between 25-50% of pulmonary involvement, 61 (33.15%) values greater than or equal to 50%, 14 (7.61%) less than 25% and 12 (6.52%) absence of signs. Regarding length of stay, 90 (48.91%) were hospitalized for less than 5 days, 80 (43.48%) between 5 and 10 days and 14 (7.61%) for 10 days or more. Seventeen (9.24%) were admitted to the Intensive Care Unit (ICU), of which 6 (35.29%) stayed for less than 5 days, 5 people (29.41%) stayed between 5-10 days. Regarding the use of ventilatory support, 86 patients (46.74%) not use any type of ventilatory support, 41.3% (76) used a nasal catheter. One hundred and seventy-nine (97.28%) used corticotherapy and 84 (45.65%) used only methylprednisolone, 21 (11.41%) dexamethasone, 11 (5.98%) used prednisone and 30 patients (16.3%) used tocilizumab.

COMMITTEE MEMBERS:
Interna - 1241733 - CLARA MONICA FIGUEREDO DE LIMA
Presidente - 1822195 - DELIO JOSE MORA AMADOR JUNIOR
Externa ao Programa - 1294737 - ERIKA MARIA SAMPAIO ROCHA - nullExterna ao Programa - 1623806 - GRASIELY FACCIN BORGES - null